What are the recommended medications for a 13-year-old female patient with influenza (flu)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 1, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Influenza in a 13-Year-Old Female

Oseltamivir 75 mg orally twice daily for 5 days is the recommended treatment, initiated as soon as possible and ideally within 48 hours of symptom onset. 1, 2, 3

Primary Antiviral Treatment

  • Oseltamivir (Tamiflu) is the antiviral drug of choice for adolescents 13 years and older with influenza 4, 1, 3
  • The standard dose is 75 mg orally twice daily for 5 days for patients weighing over 40 kg 1, 2, 3
  • Treatment can be taken with or without food, though administration with meals improves gastrointestinal tolerability and may reduce nausea 1, 3

Timing of Treatment Initiation

  • Start treatment immediately upon clinical suspicion—do not delay while awaiting laboratory confirmation 4, 1, 2
  • Greatest benefit occurs when initiated within 48 hours of symptom onset, reducing illness duration by approximately 17.6-29.9 hours 1, 5
  • Even if presenting beyond 48 hours, treatment should still be considered if the patient has moderate-to-severe or progressive symptoms 4, 1

Expected Clinical Benefits

  • Reduces illness duration by approximately 17.6-29.9 hours in otherwise healthy patients 1, 5
  • Decreases risk of pneumonia by 50% 1
  • Reduces risk of otitis media by 34% 1, 2
  • Provides significant mortality benefit in hospitalized patients (OR 0.21 for death within 15 days) 1

Alternative Antiviral Options

If oseltamivir is not available or not tolerated, consider:

  • Zanamivir (inhaled): 10 mg (two 5-mg inhalations) twice daily for 5 days, approved for patients 7 years and older 1
  • Baloxavir (oral): Single dose of 40 mg for patients 40-80 kg (or 80 mg if ≥80 kg), approved for patients 12 years and older 1
  • Peramivir (IV): Single 600 mg IV infusion over 15-30 minutes for ages 13-17 years 1

Common Side Effects and Precautions

  • Vomiting occurs in approximately 15% of treated adolescents versus 9% on placebo, but effects are mild, transient, and rarely lead to discontinuation 1
  • Other gastrointestinal symptoms include nausea, abdominal pain, and diarrhea 5
  • Despite historical concerns, controlled clinical trials have failed to establish a link between oseltamivir and neurologic or psychiatric events 2

Supportive Care Measures

  • Antipyretics can be used for fever and myalgias, but aspirin must be avoided in patients <19 years due to Reye's syndrome risk 1, 5
  • Adequate hydration and rest are important supportive measures 1
  • Monitor for warning signs requiring urgent evaluation: difficulty breathing, persistent high fever beyond 3-4 days, altered mental status, or clinical deterioration 1

Critical Pitfalls to Avoid

  • Do not withhold treatment based solely on time since symptom onset if the patient has moderate-to-severe illness or high-risk features 1
  • Do not delay treatment while awaiting laboratory confirmation in suspected cases, as clinical judgment based on symptoms and local influenza activity should guide immediate treatment decisions 4, 1, 2
  • Never use aspirin for symptom management in this age group due to Reye's syndrome risk 1, 5
  • Negative rapid antigen tests should not rule out influenza or prevent treatment, as these tests have poor sensitivity 2

References

Guideline

Management of Influenza in Adolescents

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Influenza in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Antiviral Treatment for Influenza in Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.